Evidence map›Paper›PMID 31058448›Full record

Trial reportOrthopaedic surgery2019

Study on Zoledronic Acid Reducing Acute Bone Loss and Fracture Rates in Elderly Postoperative Patients with Intertrochanteric Fractures.

Zhong Liu, Chun-Wen Li, Yi-Fan Mao, Kang Liu, Bo-Cheng Liang, Lian-Guo Wu, Xiao-Lin Shi

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Orthopaedic surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 7 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 7 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Secondary fracture risk after hip fracture in older patients: an updated sex-specific systematic review and meta analysis with GRADE and PAF assessment.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Pooled it
  2. The Healing and therapeutic effects of perioperative bisphosphonate use in patients with fragility fractures: meta-analysis of 19 clinical trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Post-fracture care programs for prevention of subsequent fragility fractures: a literature assessment of current trends.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Risk factors for imminent fractures: a substudy of the FRISBEE cohort.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zhong LiuThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Chun-Wen LiDepartment of Diagnostics of Traditional Chinese Medicine, College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China.
Yi-Fan MaoThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Kang LiuDepartment of Osteology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.ORCID https://orcid.org/0000-0002-7109-3174
Bo-Cheng LiangDepartment of Osteology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Lian-Guo WuDepartment of Osteology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Xiao-Lin ShiDepartment of Osteology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Zhejiang Chinese Medical University · CN

Funding

National Natural Science Foundation of China 81573754The State Administration of Traditional Chinese Medicine "12th Five-Year Plan" Funding Program for Key Disciplines in Traditional Chinese Medicine [2012]32Traditional Chinese Medicine of Zhejiang Province "13th Five-Year Plan" (Combined Traditional Chinese Medicine and Western Medicine) Key Discipline Construction Funding Program 2017-XK-A16Zhejiang Provincial Key Research Project of Traditional Chinese Medicine 2018ZZ012
6 · The paper itself

Abstract

objectiveTo observe the effect of zoledronic acid on the reduction of acute bone loss and fracture rate in elderly postoperative patients with intertrochanteric fracture.

methodsFrom August 2012 to January 2015, a total of 482 patients with senile osteoporotic femoral intertrochanteric fracture, who accepted proximal femoral intramedullary fixation under anesthesia were analysed. The patients were divided into two groups. Treatment group (353 cases) were treated with 100 mL/5 mg of zoledronic acid injection in 1 week after operation, as well as orally taken 600 mg/d of calcium carbonate and active vitamin D3 400 IU/d. Control group (129 cases) were given the same dose of calcium carbonate and active vitamin D3 orally. Efficacy evaluation were conducted during different periods of medication

resultsCompared with pre-medication, indexes of bone metabolism (TARP-5b, CTX) in the treatment group were brought down, especially significantly statistically different after 12 months of medication. The treatment group performed superior to control group in alleviating the pain of back and posture changing (P < 0.05), improving bone density (P < 0.05), depressing re-fracture rate (P < 0.01) after 24 months of medication. In addition, BP, PF and MH dimension scores were demonstrated with statistical significance (P < 0.05).

conclusionsThe application of zoledronic acidin elderly postoperative patients with intertrochanteric fracture can not only relieve acute bone loss, reduce the incidence rate of re-fracture, alleviate osteoporosis pain and the pain from osteoporotic fracture, but also improve bone metabolism and quality of life, which may offer an acceptable clinical opinion.

Indexed as

AgedAged, 80 and overBone Density Conservation AgentsDrug Administration ScheduleFemaleFollow-Up StudiesFracture Fixation, IntramedullaryHip FracturesHumansMaleMiddle AgedOsteoporosisOsteoporotic FracturesPostoperative CareRecurrenceSecondary PreventionBone Density Conservation AgentsZoledronic AcidBone lossIntertrochanteric fractureOsteoporosisZoledronic acid

Identifiers

PMID31058448
PMCPMC6595103
OpenAlexW2944497168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.